Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Expression of A disintegrin and metalloprotease 8 is associated with cell growth and poor survival in colorectal cancer

  • Zuli Yang1,
  • Yang Bai1,
  • Lijun Huo2,
  • Hao Chen1,
  • Jintuan Huang1,
  • Jizheng Li1,
  • Xinjuan Fan3,
  • Zihuan Yang3,
  • Lei Wang4Email author and
  • Jianping Wang4Email author
Contributed equally
BMC Cancer201414:568

DOI: 10.1186/1471-2407-14-568

Received: 12 November 2013

Accepted: 30 July 2014

Published: 7 August 2014

Abstract

Background

A disintegrin and metalloprotease 8 (ADAM8) has been reported to be associated with various malignancies. However, no studies have examined ADAM8 association in colorectal cancer (CRC). The aim of this study was to investigate the expression and function of ADAM8 in CRC.

Methods

Expression level of ADAM8 in CRC was evaluated by quantitative RT-PCR, western blot and immunohistochemical staining analysis. The role of ADAM8 in colorectal carcinogenesis was evaluated by in vitro assays. The correlations between ADAM8 status and clinicopathological features including survival were analyzed.

Results

ADAM8 was highly expressed in CRC tissues compared with adjacent normal tissues. Knockdown of ADAM8 in two CRC cell lines resulted in reduced cellular growth and proliferation, and increased apoptosis. Immunohistochemistry analysis showed no significant correlations of ADAM8 protein expression with clinicopathologic features. Survival analysis indicated that patients with ADAM8-positive tumors had worse 5-year overall survival (OS, p = 0.037) and 5-year disease free survival (DFS, p = 0.014) compared with those with ADAM8-negative tumors. Multivariate analysis indicated ADAM8 expression was an independent prognostic factor for both OS and DFS (both p< 0.001). Subgroup analysis showed that 5-year OS of colon cancer, T3-T4 stage and N0 stage was worse for patients with ADAM8-positive tumors than those with ADAM8-negative tumors (p< 0.05). The 5-year DFS in colon cancer, T3-T4 stage, N0 stage, TNM stage II, adenocarcinoma, moderate differentiation and male patient subgroups was also worse for patients with ADAM8-positive tumors than those with ADAM8-negative tumors (p < 0.05).

Conclusions

Our results show that ADAM8 is overexpressed in CRC, promotes cell growth and correlates with worse OS and DFS, and thus could serve as a biomarker for individual CRC patient therapy.

Keywords

Colorectal cancer A disintegrin and metalloprotease 8 (ADAM8) Proliferation Prognosis Overall survival Disease free survival

Background

Colorectal cancer (CRC) is the third most common cancer and the fifth leading cause of cancer-related deaths, with approximately 715,000 new cases and 70,000 deaths annually in China. The survival of CRC patients is closely correlated with conventional and clinicopathological characteristics, such as tumor location, differentiation grade and TNM stages [1]. However, in practice, CRC patients with the same pathological features may have different prognosis. To discover new treatment options and more precise assessment of this malignancy, some potential therapy targets and candidate biomarkers have been reported, such as adenomatous polyposis coli (APC) gene, K-RAS gene, p53 gene and microsatellite instability (MSI) [2]. Among these targets and candidate biomarkers, some are used to justify whether adjuvant therapy is suitable for individual CRC patients, including MSI and wild-type or mutation of K-RAS and BRAF in certain exons [35].

A disintegrin and metalloprotease 8 (ADAM8) is a member of the human ADAM family, which contains disintegrin and metalloprotease domains [6]. ADAM proteins are involved in cell adhesion, cell migration, cell fusion, membrane protein shedding and proteolysis [7, 8]. Aberrant expression of ADAM8 has been identified in solid tumors, such as gliomas, lung cancer [9], pancreatic cancer [10], renal cell carcinomas [11] and prostate carcinomas [12]. ADAM8 overexpression has been associated with poor prognosis in hepatocellular carcinoma [13], breast cancer [14] and pancreatic adenocarcinoma [10], and might act as a potential therapeutic target. Mechanistically, ADAM8 is involved in tumorigenesis by stimulating angiogenesis [14, 15], increasing cellular abilities of invasion and migration [10, 14], and inhibiting cancer cell apoptosis [16]. Previous studies showed that ADAM9 [17], ADAM10 [18], ADAM17 [19], ADAM23 [20] and ADAM29 [21] were involved in colorectal tumorigenesis and that ADAM8 was involved in lymph node metastasis of gastric cancer. However, the possible role of ADAM8 in CRC has not yet been evaluated. In the present study, we report the identification of ADAM8 as a novel biomarker and a potential prognostic indicator, and also provide evidence for its possible role in human colorectal carcinogenesis.

Methods

Tissue samples, cell culture and cDNA preparation

Thirty CRC tissue samples sets (each containing tumor and adjacent tissues) were obtained from the Sixth Affiliated Hospital of Sun Yat-sen University. Adjacent normal tissues were obtained at a distance of more than 5 cm from the tumor margin and confirmed by a pathologist. Eight human colorectal adenocarcinoma cell lines (HCT8, HT29, SW620, SW480, DLD1, HCT116, LOVO and CACO2) were purchased from the Culture Collection of Chinese Academy of Science (Shanghai, China), and cultured in RPMI 1640 supplemented with 10% fetal bovine serum (Hyclone, USA) and 1% penicillin-streptomycin at 37°C in a 5% CO2 incubator.

Total RNA from human CRC tissues cells was prepared using Trizol reagent (Invitrogen, Carlsbad, CA). Reverse transcription was performed using the ReverTra Ace qPCR RT Kit (TOYOBO CO., Osaka, Japan) according to the manufacturer’s instructions.

This study was approved by the institutional review boards of Sun Yat-Sen University (Guangzhou, China), and written informed consent was obtained from each patient in this study.

Tissue microarray (TMA)

Three hundred and forty-two CRC samples were obtained from the tumor bank of the Department of Pathology of Sun Yat-Sen University (Guangzhou, China). The patients underwent initial surgical resection for CRC between January 2000 and November 2006 and were followed up until April 2010 to collect general information, pathology reports, and information regarding the patients’ conditions after surgery. The samples were formalin-fixed and paraffin-embedded.

TMAs were constructed using an automated TMA instrument (ALPHELYS, Plaisir, France). After identifying the hematoxylin and eosin (H&E)-stained slides for optimal tumor tissue, two cylindrical core biopsies (1 mm diameter) were punched from each formalin-fixed, paraffin-embedded tissue block and arrayed in recipient TMA blocks (2 × 3 cm) as previously described [22].

RNA interference (RNAi)

ADAM8 siRNA oligonucleotides (si-ADAM8-1 sense 5’-GGACAAGCUAUAUCAGAAAdTdT-3’ and antisense 3’-dTdTCCUGUUCGAUAUAGUCUUU-5’; and si-ADAM8-2 sense 5’-GCACCUGCAUGACAACGUAdTdT-3’ and antisense 3’-dTdTCGUGGACGUACUGUUGCAU-5’) and siRNA control oligonucleotides were obtained from RiboBio Co. Ltd (Guangzhou, China). HT29 and SW480 cells (1 × 105) were cultured in six-well plates until 50% confluence and transfected with 100 nM of the indicated siRNA using LipofectamineImax (Invitrogen, CA, USA) according to the manufacturer’s instructions. The effects of siRNA silencing were analyzed after 48 h transfection. All experiments were repeated three times.

Quantitative real-time polymerase chain reaction (qRT-PCR)

PCR was performed with each reaction containing 50 ng of reverse-transcribed RNA and 1 μM 5’ and 3’ primers in a 20 μL reaction. The primers used are listed in Table 1. The reaction was performed on an ABI 7500 real-time PCR machine (Applied Biosystems, Foster City, CA, USA) using the following conditions: 95°C for 2 min, 40 cycles of 95°C for 15 sec, and 60°C for 1 min. Briefly, the relative RNA levels in each sample were determined by performing standard curves. β-actin levels were used for normalization.
Table 1

Primers used for qRT-PCR

Name

Primer sequence forward

Primer sequence reverse

ADAM8

5’-ACAATGCAGAGTTCCAGATGC-3’

5’-GGACCACACGGAAGTTGAGTT-3’

β-actin

5’-CAATGAGCTGCGTGTGGCT-3’

5’-TAGCACAGCCTGGATAGC AA-3’

Immunohistochemistry (IHC) staining

IHC was performed using the Polink-2 plus® Polymer HRP Detection System (GBI, USA) according to the manufacturer’s instructions. After deparaffinization in xylene and rehydration through a graded alcohol series, slides were transferred to sodium citrate buffer (Beijing DingguoChangsheng Biotech Co. Ltd, AR-0511) for 15 min in the microware and left at room temperature for 30 min. After blocking endogenous peroxidase, slides were incubated with 10 μg/ml goat polyclonal antibody specific to human ADAM8 (R&D Systems, Inc., Minneapolis, MN) at 4°C overnight. Slides were washed three times with phosphate-buffered saline (PBS) and incubated with Polymer Helper (reagent 1, Polink-2 plus® supply) and Poly-HRP anti-Goat IgG (reagent 2, Polink-2 plus® supply) for 30 min. Then the slides were stained with DAB and counterstained with hematoxylin. A negative control using antibody dilution as a substitute for primary antibody was performed for each experiment.

ADAM8 staining was examined by two pathologists blinded to clinicopathological data. Representative fields were captured under low power (100 × magnification) and high power (400 × magnification) by a Leica DMI 4000B inverted microscope (Leica Micro-systems, Wetzlar, Germany). Disagreements were reevaluated until a consensus was reached. IHC staining was analyzed using the Image Pro-Plus (version 6.0, Media Cybernetics, Silver Spring, USA) introduced by Xavier [23]. Briefly, the tumor area was selected as the area of interest (AOI), and the area sum and integrated optical density (IOD) of the AOI were selected as the measurement parameters. ADAM8 expression index equaled the quotient between the IOD and the total area of AOI. The mean expression index for each duplicate was used for statistical analysis. Selection of cutoff value was performed according to a previous study [24]. The cutoff point was 9.79 based on the patient’s OS and DFS reaching significant difference. The CRC tissues were classified based on ADAM8 density into the negative group (less than or equal to 9.79) or positive group (more than 9.79). The ADAM8 positive group in cancer tissues and normal tissues was divided into three subgroups of weak (9.79–64.5), moderate (64.5–111.2) and strong (111.2–256.7) expression according to the IHC scores based on OS and DFD reaching significant difference.

Western blot

After 72 h transfection, HT29 and SW480 cells were washed three times with PBS and lysed with RIPA buffer (Dingguo, Beijing, China) supplemented with phenylmethanesulfonyl fluoride (PMSF, Dingguo, Beijing, China). ADAM8 protein levels were determined using two-color fluorescent western blotting on the Odyssey infrared imaging system (LI-COR, Nebraska, USA). In brief, protein samples were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene fluoride (PVDF) membrane (Pall, New York, USA). Membranes were then blocked with 5% skim milk for 1 h. Proteins were detected using mouse monoclonal antibodies specific to human ADAM8 (diluted 1:250, Abcam, UK, ab89127) and β-actin (diluted 1:10,000, Protein Tech, Chicago, USA). After incubating with primary antibodies overnight at 4°C and species-appropriate fluorescently conjugated secondary antibodies for 1 h at room temperature, the blots were observed using the Odyssey infrared imaging system. Secondary antibodies were purchased from Santa Cruz Biotechnology (CA, USA) unless otherwise indicated.

Cell viability and cell proliferation assay

HT29 and SW480 cells were seeded in 96-well plates at a density of 1 × 104 cells/well. Cells were transfected with ADAM8 siRNA and cell viability was determined 0, 1, 2, 3, and 4 days later using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay kit (Promega, Madison, WI) according to the manufacturer’s protocol. After 72 h of transfection with ADAM8 siRNA, cell proliferation assay was performed using an EDU (5-ethynyl-2’-deoxyuridine) Cell Proliferation Kit (Invitrogen, Camarillo, CA) according to the manufacturer’s instructions. Data are presented as mean ± SD for three independent experiments compared with the control group, and each experiment was performed in triplicate.

Cell apoptosis assay

HT29 and SW480 cells transfected with ADAM8 siRNA were seeded in 12-well plates at a density of 1 × 104 viable cells/well. After 72 h culture, the cells were fixed in 70% ethanol and stained with 50 mg/ml propidium iodide (BD Pharmingen, San Jose, CA, USA), then sorted by FACSCalibur (BD Biosciences, Franklin Lakes, NJ, USA). Cell cycle profiles were analyzed by ModFit 3.0 software (Verity Software House, Topsham, ME, USA). Apoptosis was determined by dual staining with Annexin V:FITC and propidium iodide (Invitrogen). The Annexin V-positive cells were counted as apoptotic cells.

Statistical analyses

SPSS 16.0 for Windows (SPSS, Inc., Chicago, IL) was used for statistical analyses. Continuous variables were expressed as mean ± SD and analyzed by t-test. The Chi-square test was used to show differences of categorical variables. Survival analysis was performed using the Kaplan-Meier method and compared using the log-rank test. P< 0.05 was considered statistically significant.

Results

Expression status of ADAM8 gene in human CRC tissues and cell lines

We evaluated the expression of ADAM8 protein and mRNA levels in 30 pairs of fresh-frozen CRC tissues and adjacent normal tissues by IHC and qRT-PCR. IHC results showed that specific ADAM8 staining was mainly detected in the cytoplasm and membrane of noncancerous and malignant epithelial cells. IHC staining indicated more CRC tissues with positive ADAM8 expression than in corresponding adjacent normal tissues (81.0% vs. 33.3%, respectively; p< 0.0001) (Figure 1A, Table 2). Among the 24 CRC patients with ADAM8 positive tumor tissues, high and moderate expression of ADAM8 was detected in 20 cases and weak expression in 4 cases. Among paired adjacent normal tissues, weak expression of ADAM8 protein was found in 10 cases, while no cases showed high or moderate expression. The mRNA expression levels of ADAM8 were evaluated by qRT-PCR and representative data are shown in Figures 1B and 1C. The mean expression levels of ADAM8 mRNA were significantly higher in tumor tissues compared with those in adjacent normal tissues (2.74 ± 0.17 vs. 1.04 ± 0.09, respectively; p = 0.0018). The expression of ADAM8 mRNA was normalized to β-actin mRNA, which served as a control for the input cDNA.
https://static-content.springer.com/image/art%3A10.1186%2F1471-2407-14-568/MediaObjects/12885_2013_Article_4773_Fig1_HTML.jpg
Figure 1

ADAM8 expression status in CRC tumor and normal tissues. A, Expression of ADAM8 in tumor and normal colon tissues detected by IHC. Representative images of IHC staining of colon tissues with anti-ADAM8 antibody on tumor and normal tissues (100× for left panel and 400× for right panel). B, Mean expression levels of ADAM8 mRNA in tumor tissues were significantly higher than that observed in normal tissues (p = 0.0018). The expression of ADAM8 mRNA was normalized to β-actin mRNA, which served as a control for the input cDNA.

Table 2

Comparison of ADAM8 protein level in normal and tumor tissues by IHC (n = 42)

Tissue

ADAM8 expression

χ2

p value

Negative

Positive

Normal

20(66.7%)

10(33.3%)

13.3

<0.0001

Tumor

6(19.0%)

24(81.0%)

  
Expression levels of ADAM8 mRNA and protein were also measured in eight CRC cell lines (Figure 2A). The expression level of ADAM8 protein was consistent with mRNA expression level in HCT8, HT29, SW620, SW480, HCT 116 and CACO2 cell lines, but not in DLD1 and LOVO cell lines. Based on these results, we selected HT29 and SW480 cell lines for further analysis. To explore the potential effect of ADAM8 on CRC carcinogenesis, two ADAM8 siRNA oligonucleotides were generated to knockdown ADAM8 expression in HT29 and SW480 cells. Transfection with si-ADAM8-1 decreased ADAM8 mRNA expression levels by 84.3% in HT29 cells (p < 0.001) and by 82.7% in SW480 cells (p < 0.001) compared with control siRNA. Transfection with si-ADAM8-2 decreased ADAM8 mRNA levels by 82.7% in HT29 cells (p < 0.001) and by 78.8% in SW480 cells (p < 0.001) (Figure 2B and C, top panel). Western blot analysis confirmed the qRT-PCR results (Figure 2B and C, bottom panel).
https://static-content.springer.com/image/art%3A10.1186%2F1471-2407-14-568/MediaObjects/12885_2013_Article_4773_Fig2_HTML.jpg
Figure 2

Expression of ADAM8 in CRC cell lines. A, Expression of ADAM8 mRNA (top) and protein level (bottom) in HCT8, HT29, SW620, SW480, DLD1, HCT116, LOVO and CACO2 cell lines. B, C, Significantly decreased expression of ADAM8 mRNA (top) and protein levels (bottom) in ADAM8 siRNA-transfected HT29 cells (B) and SW480 cells (C) compared with the control group (p < 0.001). The expression of ADAM8 mRNA was normalized to β-actin mRNA, which served as the control. Data are expressed as the mean ± standard deviation (SD).

Knockdown of ADAM8 influences proliferation and apoptosis of CRC cells

Cell proliferation assays revealed that si-ADAM8-1-mediated decreased expression of ADAM8 significantly inhibited cell proliferation in HT29 cells (down to 30.5%; p < 0.01), and si-ADAM8-2 transfection also inhibited proliferation (down to 48.6%; p < 0.001) (Figure 3A). Similar results were observed in SW480 cells transfected with si-ADAM8-1 (down to 45.6%; p < 0.001) and si-ADAM8-2 (down to 45.2%; p < 0.001) (Figure 3A). Cell viability assay demonstrated that knockdown of ADAM8 significantly inhibited cell growth in both SW480 (Figure 3B) and HT29 cells (Figure 3C). Cell cycle and apoptosis assay showed that the percentage of cell apoptosis in siADAM8-transfected HT29 and SW480 cells was significantly higher than that in control cells (Figure 3D). Together these results suggest that ADAM8 is involved in CRC carcinogenesis by accelerating proliferation/growth and inducing apoptosis of CRC cells.
https://static-content.springer.com/image/art%3A10.1186%2F1471-2407-14-568/MediaObjects/12885_2013_Article_4773_Fig3_HTML.jpg
Figure 3

ADAM8 influences proliferation and apoptosis of CRC cells. ADAM8 siRNA-mediated reduction of ADAM8 significantly inhibited proliferation (A) and growth (B and C) of HT29 and SW480 cells compared with the control group. D, Knockdown of ADAM8 significantly induced cell apoptosis in HT29 and SW480 cells compared with controls.

Correlation of ADAM8 expression with clinicopathological characteristics and long-term survival of CRC

The association between ADAM8 expression and clinicopathological characteristics was assessed in 342 primary CRC patients. IHC was used to detect ADAM8 protein expression status, and tissues were scored as positive or negative as described in Materials and Methods. Among 342 CRC patients, ADAM8 was positive in 261 cases (76.3%) and negative in 81 cases (23.7%). However, no significant correlations were found between ADAM8 expression status and clinicopathological indicators (Table 3). The correlation of ADAM8 protein expression and postoperative survival was also evaluated. Five-year overall survival (OS) and disease-free survival (DFS) for all patients were 73% and 70%, respectively. The 5-year OS for patients with ADAM8 positive tumors was significantly poorer than those with ADAM8 negative tumors (70% vs. 81%, respectively; p = 0.037) (Figure 4A). Similar results were found for the 5-year DFS of CRC patients with positive and negative ADAM8 tumors (53% vs. 80%, respectively; p = 0.014) (Figure 4B).
Table 3

Association between ADAM8 expression in CRC and clinicopathologic characteristics (n = 342)

Indicator

ADAM8 expression

χ2

pvalue

Negative (n = 81)

Positive (n = 261)

Gender

  

1.448

0.229

  Male

49(60.5%)

138(52.9%)

  

  Female

32(39.5%)

123(47.1%)

  

Age

  

0.769

0.380

  ≤65 yrs

51(63.0%)

150(57.5%)

  

  >65 yrs

30(37.0%)

111(42.5%)

  

Location

  

0.646

0.421

  Colon

42(52.9%)

122(46.7%)

  

  Rectum

39(48.1%)

139(53.3%)

  

T stage

  

0.465

0.495

  T1-T2

16(19.8%)

43(16.5%)

  

  T3- T4

65(80.2%)

218(83.5%)

  

N stage

  

1.675

0.196

  N0

54(66.7%)

153(58.7%)

  

  N1- N2

27(33.3%)

108(41.3%)

  

M stage

  

0.256

0.613

  M0

68(84.0%)

225(86.2%)

  

  M1

13(16.0%)

36(13.8%)

  

TNM stage

  

0.544

0.909

  I

8(9.9%)

33(12.6%)

  

  II

33(40.7%)

107(41.0%)

  

  III

28(34.6%)

83(31.8%)

  

  IV

12(14.8%)

38(14.6%)

  

Differentiation grade

  

2.863

0.239

  Well

5(12.3%)

25(7.8%)

  

  Moderately

71(75.4%)

207(83.0%)

  

  Poorly

5(12.3%)

29(9.2%)

  

Histological type

  

1.209

0.272

  Adenocarcinoma

72(88.9%)

219(83.9%)

  

  Mucinous/Signet-ring adenocarcinoma

9(11.1%)

42(16.1%)

  

CA19-9 (ug/L)

  

3.582

0.058

  ≤60

67(82.2%)

236(90.4%)

  

  >60

14(17.8%)

25(9.6%)

  

CEA (ug/L)

  

0.225

0.635

  ≤5

52(64.2%)

175(67.0%)

  

  >5

29(35.8%)

86(33.0%)

  
https://static-content.springer.com/image/art%3A10.1186%2F1471-2407-14-568/MediaObjects/12885_2013_Article_4773_Fig4_HTML.jpg
Figure 4

Survival of CRC patients according to the expression status of ADAM8 protein. A, CRC patients with positive ADAM8 had poorer OS than those with negative ADAM8 (p = 0.037). B, CRC patients with positive ADAM8 had poorer DFS than those with negative ADAM8 (p = 0.014).

Regarding 5-year OS, univariate analysis indicated that T stage, N stage, M stage, TNM stage, differentiation grade, preoperative CEA and CA19-9 levels, and ADAM8 protein expression status were found to be prognostic factors (Table 4). However, multivariate analysis demonstrated that TNM stage, preoperative CEA levels and ADAM8 protein expression status (HR = 1.943; 95% CI: 1.089–3.465, p = 0.024) were independent prognostic indicators (Table 4). Further analysis for OS in each subgroup showed that patients with ADAM8 positive tumors have poorer 5-year OS than those with negative ADAM8 in colon cancer (p = 0.006) (Figure 5A), T3/T4 stage (p = 0.023) (Figure 5B) and N0 stage (p = 0.032) (Figure 5C) subgroups compared with rectal cancer, T1/T2 stage and N1-2 stage patients. No significant correlation was found with other subgroups.
Table 4

Univariate and multivariate analyses of the prognostic factors for 5-year OS of CRC patients (n = 342)

Indicator

Univariate analysis

Multivariate analysis

5-year OS

p value

HR

95% CI

p value

T stage

     

  T1-T2

79%

0.009

  

NS

  T3-T4

64%

    

N stage

     

  N0

78%

<0.0001

  

NS

  N1-N2

61%

    

M stage

     

  M0

73%

<0.0001

  

NS

  M1

23%

    

Differentiation grade

     

  Well

74%

0.004

  

NS

  Moderately

72%

    

  Poorly

47%

    

TNM stage

     

  I

86%

<0.0001

1

Reference

<0.0001

  II

78%

 

1.016

0.411-2.511

 

  III

69%

 

1.674

0.686-4.083

 

  IV

22%

 

9.685

3.773-24.862

 

CEA(ug/L)

     

  ≤5

80%

<0.0001

1

Reference

0.006

  >5

54%

 

1.144

0.465-2.811

 

CA19-9 (ug/L)

 

0.040

   

  ≤60

72%

   

NS

  >60

59%

    

ADAM8 protein

     

  Negative

81%

0.037

1

Reference

0.024

  Positive

67%

 

1.943

1.089-3.465

 

CRC, colorectal cancer; HR, hazard ratio; CI, confidence interval; NS, not significant.

https://static-content.springer.com/image/art%3A10.1186%2F1471-2407-14-568/MediaObjects/12885_2013_Article_4773_Fig5_HTML.jpg
Figure 5

Five-year OS of patients with positive ADAM8 versus negative ADAM8 tumors in (A) colon cancer ( p= 0.006), (B) T3/4 depth of invasion ( p= 0.023) and (C) N0 stage ( p= 0.032).

Regarding 5-year DFS, N stage, differentiation grade, TNM stage, preoperative CEA and CA19-9 levels, and ADAM8 protein expression status were found to be prognostic factors by univariate analysis (Table 5). However, TNM stage, preoperative CEA levels and ADAM8 protein expression status (HR = 2.108; 95% CI: 1.922–3.480, p = 0.025) were independent prognostic indicators by multivariate analysis (Table 5). Further analysis for DFS in subgroups showed that patients with positive ADAM8 expression had poorer 5-year DFS than those with negative ADAM8 expression in colon cancer (p = 0.001) (Figure 6A), T3/T4 stage (p = 0.009) (Figure 6B), N0 stage (p = 0.010) (Figure 6C), TNM II stage (p = 0.045) (Figure 6D), adenocarcinoma (p = 0.027) (Figure 6E), moderate differentiation (p = 0.043) (Figure 6F) and male CRC patients (p = 0.030) (Figure 6G) subgroups. No significant correlations were found with other indicators.
Table 5

Univariate and multivariate analyses of the prognostic factors for 5-year DFS of CRC patients (n = 292)

Indicator

Univariate analysis

Multivariate analysis

5-year DFS

p value

HR

95% CI

p value

N stage

     

  N0

68%

0.031

  

NS

  N1-N2

59%

    

Grade

     

  Well

71%

0.003

  

NS

  Moderately

57%

    

  Poorly

46%

    

TNM stage

     

  I

85%

0.017

1

Reference

0.027

  II

72%

 

2.445

0.958-6.236

 

  III

61%

 

2.482

0.954-6.457

 

CEA(ug/L)

     

  ≤5

75%

<0.0001

1

Reference

0.001

  >5

52%

 

2.052

1.342-3.145

 

CA19-9 (ug/L)

     

  ≤60

69%

0.016

  

NS

  >60

55%

    

ADAM8 protein

     

  Negative

81%

0.014

1

Reference

0.025

  Positive

67%

 

2.108

1.922-3.480

 

CRC, colorectal cancer; HR, hazard ratio; CI, confidence interval; NS, not significant.

https://static-content.springer.com/image/art%3A10.1186%2F1471-2407-14-568/MediaObjects/12885_2013_Article_4773_Fig6_HTML.jpg
Figure 6

Five-year DFS of patients with positive ADAM8 versus negative ADAM8 tumors in (A) colon cancer ( p= 0.001), (B) T3/4 stage ( p= 0.009), (C) N0 stage ( p= 0.032), (D) TNM II stage ( p= 0.045), (E) adenocarcinoma ( p= 0.027), (F) moderate differentiation ( p= 0.043) and (G) male CRC patients ( p= 0.030).

Discussion

A member of the ADAM family, ADAM8 has been detected in many cell types and various types of cancer [12, 2530]. However, no study of ADAM8 expression in CRC patients has been performed. In the present study, expression of both protein and mRNA levels of ADAM8 in 30 CRC patients were significantly higher in cancerous tissues than corresponding adjacent normal tissues, suggesting its importance in CRC carcinogenesis. IHC analysis of 342 CRC patients identified 261 (76.3%) cases with positive ADAM8 expression and 81 (23.7%) with negative ADAM8 expression, indicating that ADAM8 is upregulated in human CRC. To explore the potential role of ADAM8 in CRC carcinogenesis, cell proliferation and apoptosis assay were used to assess the influence of ADAM8 on cell growth. Our findings showed that siRNA-mediated downregulation of ADAM8 in CRC cells significantly suppressed cell proliferation and induced cell apoptosis, which is in agreement with previous reports [13, 16]. These data strongly suggest that ADAM8 is involved in CRC carcinogenesis and regulates cell growth by accelerating cell proliferation and inhibiting cell apoptosis. Although previous studies have shown that ADAM8 increases invasion and migration abilities of tumor cells [14, 15, 21], we did not find a significant decrease of invasion and migration in ADAM8 siRNA-transfected cells compared with control cells (data not shown).

In the present study, we explored the relationship between ADAM8 expression status and clinicopathological features in CRC. Although previous studies reported that ADAM8 expression correlates significantly with tumor size, histological differentiation, regional and distant metastasis, tumor stages in several cancers progression [12, 13, 29, 31], we did not find any significant correlations between ADAM8 expression status and any clinicopathological feature in CRC.

In the present study, patients with ADAM8 positive tumors have poorer 5-year OS and DFS than those with ADAM8 negative tumors. Multivariate analysis revealed that ADAM8 positive expression could act as an important factor for unfavorable prognosis in both OS and DFS for CRC patients independent of some conventional indicators, which is in agreement with published papers [25, 29, 30]. Further analysis of survival in patient subgroups suggested that ADAM8 is a prognostic factor for colon cancer but not for rectal cancer, indicating that ADAM8 may not function as a biomarker for rectal cancer. Meanwhile, positive ADAM8 was an adverse indicator for both OS and DFS in T3/T4 depth of invasion and N0 stage, and only for DFS in adenocarcinoma, moderately differentiated tumors and male patients. Based on these results, ADAM8 can be considered as a novel prognostic marker for CRC and may serve as a target for individual therapy for certain CRC patients.

Although we explored the expression status, potential roles and clinical implications of ADAM8 in CRC, the underlying mechanism by which ADAM8 influences tumor cell growth and postoperative survival of CRC patients was not investigated in this study. Furthermore, although high expression of ADAM8 induces tumor cell resistance to chemotherapy [16], we were unable to assess the role of post-operative adjuvant chemotherapy with regard to DFS and OS in context of ADAM8 expression in univariate and multivariate analyses due to the shortage of post-operative adjuvant chemotherapy data for 342 CRC patients in this study. More studies investigating these questions should be performed in the future.

Conclusions

In summary, our results show that ADAM8 is overexpressed in CRC tissues, promoting cancer cell proliferation, inducing cell apoptosis and correlating with worse OS and DFS. Furthermore, ADAM8 may be considered as a novel prognostic marker for CRC and could function as a target of individual therapy for certain CRC patients.

Notes

Abbreviations

ADAM8: 

A disintegrin and metalloprotease 8

CRC: 

Colorectal cancer

OS: 

Overall survival

DFS: 

Disease-free survival

qRT-PCR: 

Quantitative RT-PCR.

Declarations

Acknowledgements

This study was partly supported by grants from the Natural Science Fund Committee of Guangdong province (No. 10251008901000008) and the Science and Technology Planning Project of Guangdong Province (No. 2013B031600171), China.

Authors’ Affiliations

(1)
Department of Gastrointestinal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University (Guangdong Gastrointestinal and Anal Hospital), Sun Yat-Sen University Guangzhou
(2)
Department of Ophthalmology, The First Affiliated Hospital of Sun Yat-sen University, Sun Yat-Sen University Guangzhou
(3)
Gastrointestinal Institute, Sun Yat-Sen University Guangzhou
(4)
Department of Colon & Rectum Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University (Guangdong Gastrointestinal and Anal Hospital), Sun Yat-Sen University Guangzhou

References

  1. Yang ZL, Wang JP, Wang L, Dong WG, Huang YH, Qin JZ, Zhan WH: Multivariate regression analysis of prognostic factors in colorectal cancer. Chin-Ger J Clin Oncol. 2003, 2 (3): 44-51.Google Scholar
  2. Popat S, Hubner R, Houlston RS: Systematic review of micro-satellite instability and colorectal cancer prognosis. J Clin Oncol. 2005, 23: 609-618.View ArticlePubMedGoogle Scholar
  3. Kelley RK, Wang G, Venook AP: Biomarker Use in Colorectal Cancer Therapy. J Natl Compr Canc Netw. 2011, 9 (11): 1293-1302.PubMedPubMed CentralGoogle Scholar
  4. Yokota T: Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?. Anticancer Agents Med Chem. 2012, 12 (2): 163-171.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Zlobec I, Bihl MP, Schwarb H, Terracciano L, Lugli A: Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer. 2010, 127 (2): 367-380.PubMedGoogle Scholar
  6. Schlomann U, Rathke-Hartlieb S, Yamamoto S, Jockusch H, Bartsch JW: Tumor necrosis factor alpha induces a metalloprotease-disintegrin, ADAM8 (CD156): implications for neuronglia interactions during neurodegeneration. J Neurosci. 2000, 20: 7964-7971.PubMedGoogle Scholar
  7. Dehmel T, Janke A, Hartung HP, Goebel HH, Wiendl H, Kieseier BC: The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies. Neurobiol Dis. 2007, 25: 665-674.View ArticlePubMedGoogle Scholar
  8. Dijkstra A, Postma DS, Noordhoek JA, Lodewijk ME, Kauffman HF, ten Hacken NH, Timens W: Expression of ADAMs (“a disintegrin and metalloprotease”) in the human lung. Virchows Arch. 2009, 454: 441-449.View ArticlePubMedGoogle Scholar
  9. Ishikawa N, Daigo Y, Yasui W, Inai K, Nishimura H, Tsuchiya E, Kohno N, Nakamura Y: ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res. 2004, 10: 8363-8370.View ArticlePubMedGoogle Scholar
  10. Valkovskaya N, Kayed H, Felix K, Hartmann D, Giese NA, Osinsky SP, Friess H, Kleeff J: ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer. J Cell Mol Med. 2007, 11 (5): 1162-1174.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Roemer A, Schwettmann L, Jung M, Stephan C, Roigas J, Kristiansen G, Loening SA, Lichtinghagen R, Jung K: The membrane proteases adams and hepsin are differentially expressed in renal cell carcinoma. Are they potential tumor markers?. J Urol. 2004, 172: 2162-2166.View ArticlePubMedGoogle Scholar
  12. Fritzsche FR, Jung M, Xu C, Rabien A, Schicktanz H, Stephan C, Dietel M, Jung K, Kristiansen G: ADAM8 expression in prostate cancer is associated with parameters of unfavorable prognosis. Virchows Arch. 2006, 449 (6): 628-636.View ArticlePubMedGoogle Scholar
  13. Zhang Y, Tan YF, Jiang C, Zhang K, Zha TZ, Zhang M: High ADAM8 expression is associated with poor prognosis in patients with hepatocellular carcinoma. Pathol Oncol Res. 2013, 19 (1): 79-88.View ArticlePubMedGoogle Scholar
  14. Romagnoli M, Mineva ND, Polmear M, Conrad C, Srinivasan S, Loussouarn D, Barillé-Nion S, Georgakoudi I, Dagg A, McDermott EW, Duffy MJ, McGowan PM, Schlomann U, Parsons M, Bartsch JW, Sonenshein GE: ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis. EMBO Mol Med. 2014, 6 (2): 278-294.PubMedGoogle Scholar
  15. Guaiquil VH, Swendeman S, Zhou W, Guaiquil P, Weskamp G, Bartsch JW, Blobel CP: ADAM8 is a negative regulator of retinal neovascularization and of the growth of heterotopically injected tumor cells in mice. J Mol Med (Berl). 2010, 88 (5): 497-505.View ArticleGoogle Scholar
  16. Zhang W, Wan M, Ma L, Liu X, He J: Protective effects of ADAM8 against cisplatin-mediated apoptosis in non-small-cell lung cancer. Cell Biol Int. 2013, 37 (1): 47-53.View ArticlePubMedGoogle Scholar
  17. Hirao T, Nanba D, Tanaka M, Ishiguro H, Kinugasa Y, Doki Y, Yano M, Matsuura N, Monden M, Higashiyama S: Overexpression of ADAM9 enhances growth factor-mediated recycling of E-cadherin in human colon cancer cell line HT29 cells. Exp Cell Res. 2006, 312 (3): 331-339.PubMedGoogle Scholar
  18. Gavert N, Sheffer M, Raveh S, Spaderna S, Shtutman M, Brabletz T, Barany F, Paty P, Notterman D, Domany E, Ben-Ze’ev A: Expression of L1-CAM and ADAM10 in human colon cancer cells induce metastasis. Cancer Res. 2007, 67 (16): 7703-7712.View ArticlePubMedGoogle Scholar
  19. Van Schaeybroeck S, Kyula JN, Fenton A, Fenning CS, Sasazuki T, Shirasawa S, Longley DB, Johnston PG: Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17. Cancer Res. 2011, 71 (3): 1071-1080.View ArticlePubMedGoogle Scholar
  20. Choi JS, Kim KH, Jeon YK, Kim SH, Jang SG, Ku JL, Park JG: Promoter hypermethylation of the ADAM23 gene in colorectal cancer cell lines and cancer tissues. Int J Cancer. 2009, 124 (6): 1258-1262.View ArticlePubMedGoogle Scholar
  21. Ashktorab H, Schäffer AA, Daremipouran M, Smoot DT, Lee E, Brim H: Distinct genetic alterations in colorectal cancer. PLoS One. 2010, 5 (1): e8879-View ArticlePubMedPubMed CentralGoogle Scholar
  22. Gillett CE, Springall RJ, Barnes DM, Hanby AM: Multiple tissue core arrays in histopathology research: avalidation study. J Pathol. 2000, 192: 549-553.View ArticlePubMedGoogle Scholar
  23. Xavier LL, Viola GG, Ferraz AC, Da Cunha C, Deonizio JM, Netto CA, Achaval M: A simple and fast densitometric method for the analysis of tyrosine hydroxylase immunoreactivity in the substantia nigra pars compacta and in the ventral tegmental area. Brain Res Brain Res Protoc. 2005, 16 (1–3): 58-64.View ArticlePubMedGoogle Scholar
  24. Wu X, Zou Y, He X, Yuan R, Chen Y, Lan N, Lian L, Wang F, Fan X, Zeng Y, Ke J, Wu X, Lan P: Tumor-infiltrating mast cells in colorectal cancer as a poor prognostic factor. Int J Surg Pathol. 2013, 21 (2): 111-120.View ArticlePubMedGoogle Scholar
  25. Wildeboer D, Naus S, Amy Sang QX, Bartsch JW, Pagenstecher A: Metalloproteinase disintegrins ADAM8 and ADAM19 are highly regulated in human primary brain tumors and their expression levels and activities are associated with invasiveness. J Neuropathol Exp Neurol. 2006, 65: 516-527.View ArticlePubMedGoogle Scholar
  26. Valkovskaya NV: Hypoxia-dependent expression of ADAM8 in human pancreatic cancer cell lines. Exp Oncol. 2008, 30: 129-132.PubMedGoogle Scholar
  27. Hernández I, Moreno JL, Zandueta C, Montuenga L, Lecanda F: Novel alternatively spliced ADAM8 isoforms contribute to the aggressive bone metastatic phenotype of lung cancer. Oncogene. 2010, 29: 3758-3769.View ArticlePubMedGoogle Scholar
  28. Zielinski V, Brunner M, Heiduschka G, Schneider S, Seemann R, Erovic B, Thurnher D: ADAM8 in squamous cell carcinoma of the head and neck: a retrospective study. BMC Cancer. 2012, 12: 76-View ArticlePubMedPubMed CentralGoogle Scholar
  29. Li Z, Liao Q, Wu Y, Liao M, Hao Y, Zhang S, Song S, Li B, Zhang YD: Upregulation of a disintegrin and metalloprotease 8 influences tumor metastasis and prognosis in patients with osteosarcoma. Pathol Oncol Res. 2012, 18: 657-661.View ArticlePubMedGoogle Scholar
  30. He S, Ding L, Cao Y, Li G, Deng J, Tu Y, Wang B: Overexpression of a disintegrin and metalloprotease 8 in human gliomas is implicated in tumor progression and prognosis. Med Oncol. 2012, 29: 2032-2037.View ArticlePubMedGoogle Scholar
  31. Li W, Ye F, Wang D, Sun X, Tong W, Lian G, Jiang J, Suo J, Zhang DY: Protein predictive signatures for lymph node metastasis of gastric cancer. Int J Cancer. 2013, 132 (8): 1851-1859.View ArticlePubMedGoogle Scholar
  32. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/568/prepub

Copyright

© Yang et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement